PI3-kinase class I · PROTEIN COMPLEX GROUP · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14PI3-kinase class I shows late clinical disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 12 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P27986. Start with breast cancer, then reuse UniProt P27986 as the stable protein anchor across project notes and exports.
Start with breast cancer, then reuse UniProt P27986 as the stable protein anchor across project notes and exports.
PI3-kinase class I shows late clinical disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 12 linked drugs remain visible in the same block.
Start review with breast cancer because it currently carries late clinical support. Linked drugs include APITOLISIB, BGT-226, BUPARLISIB, DACTOLISIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPhosphatidylinositol 3-kinase regulatory subunit alpha
Review this target as PI3-kinase class I, mapped to UniProt P27986. ChEMBL maps the protein component as Phosphatidylinositol 3-kinase regulatory subunit alpha. Sequence length is 724 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats PI3-kinase class I as ChEMBL target CHEMBL3559703, mapped to UniProt P27986. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether PI3-kinase class I is the right protein anchor across sources, using UniProt P27986 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why breast cancer is currently framed as late clinical support. It currently carries 12 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | PI3-kinase class I |
| Target Type | PROTEIN COMPLEX GROUP |
| Organism | Homo sapiens |
| UniProt | P27986 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Phosphatidylinositol 3-kinase regulatory subunit alpha |
| UniProt Accession | P27986 |
| Component Type | Protein |
| Sequence Length | 724 aa |
Phosphatidylinositol 3-kinase regulatory subunit alpha
Review this target as PI3-kinase class I, mapped to UniProt P27986. ChEMBL maps the protein component as Phosphatidylinositol 3-kinase regulatory subunit alpha. Sequence length is 724 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
PI3-kinase class I shows late clinical disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.
Start review with breast cancer because it currently carries late clinical support. Linked drugs include APITOLISIB, BGT-226, BUPARLISIB, DACTOLISIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3683580 | 8.22 | IC50 | 6.0 | Preclinical |
| CHEMBL3683671 | 8.15 | IC50 | 7.0 | Preclinical |
| CHEMBL3683555 | 7.96 | IC50 | 11.0 | Preclinical |
| CHEMBL3683606 | 7.89 | IC50 | 13.0 | Preclinical |
| CHEMBL3683649 | 7.89 | IC50 | 13.0 | Preclinical |
| CHEMBL3683695 | 7.89 | IC50 | 13.0 | Preclinical |
| CHEMBL3683596 | 7.85 | IC50 | 14.0 | Preclinical |
| CHEMBL3683693 | 7.85 | IC50 | 14.0 | Preclinical |
| CHEMBL3683611 | 7.82 | IC50 | 15.0 | Preclinical |
| CHEMBL3683686 | 7.82 | IC50 | 15.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 4 | 428 | 6.3 |